Doctors typically classify SVT as a benign condition. However, it has associations with venous thromboembolic disorders, including deep vein thrombosis (DVT) and pulmonary embolism (PE).

Etripamil nasal spray was associated with improving symptoms and reducing ED visits to terminate nodal-dependent paroxysmal supraventricular tachycardia outside the health care environment ...

A fast-acting nasal spray was safe and effective for patients self-treating for repeated episodes of paroxysmal supraventricular tachycardia during long-term follow-up, according to findings from ...

Etripamil nasal spray (Milestone Pharmaceuticals) continues to show promise as a way for patients to treat their own paroxysmal supraventricular tachycardia (PSVT) without the need for an emergency ...

A nasal spray containing etripamil, an investigational calcium channel blocker, significantly benefits patients with paroxysmal supraventricular tachycardia (PSVT), according to top-line results of ...

In five clinical trials involving 317 patients with SVT, Rapiblyk reduced heart rate in 40% to 90% of them within about 10 minutes, compared to a placebo that reduced heart rate in 0%-11% of them ...